PB1878: CROSS-TRIAL ANALYSIS OF FIXED-DURATION IBRUTINIB (I) PLUS VENETOCLAX (V) VS FLUDARABINE (F), CYCLOPHOSPHAMIDE (C), AND RITUXIMAB (R) AS FIRST-LINE TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

PB1878: CROSS-TRIAL ANALYSIS OF FIXED-DURATION IBRUTINIB (I) PLUS VENETOCLAX (V) VS FLUDARABINE (F), CYCLOPHOSPHAMIDE (C), AND RITUXIMAB (R) AS FIRST-LINE TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

التفاصيل البيبلوغرافية
المؤلفون الرئيسيون: J. C. Barrientos, P. M. Barr, A. R. Mato, C. S. Tam, P. Ghia, C. Moreno, N. E. Kay, T. Siddiqi, E. Szafer-Glusman, C. Zhou, L. Neumayr, G. Krigsfeld, W. G. Wierda, T. Shanafelt
التنسيق: مقال
اللغة:English
منشور في: Wiley 2022-06-01
سلاسل:HemaSphere
الوصول للمادة أونلاين:http://journals.lww.com/10.1097/01.HS9.0000850364.78915.d9

الانترنت

http://journals.lww.com/10.1097/01.HS9.0000850364.78915.d9

مواد مشابهة